ROTH Capital Partners

Jonathan Aschoff, Ph.D., (646) 616-2795
jaschoff@roth.com
Sales (800) 933-6830, **Trading** (800) 933-6820

COMPANY NOTE | EQUITY RESEARCH | September 17, 2020

Healthcare: Biotechnology

Oryzon Genomics SA | ORY.SM - €2.87 - MADRID | *Buy*

Company Update

Stock Data	
52-Week Low - High	€1.48 - €3.90
Shares Out. (mil)	53.06
Mkt. Cap.(mil)	€152.29
3-Mo. Avg. Vol.	264,538
12-Mo.Price Target	€15.00
Cash (mil)	$54.9
Tot. Debt (mil)	$13.2

EPS $

Yr Dec	—2019—	—2020E—	—2021E—
		Curr	Curr
1Q	(0.04)A	(0.03)A	-
2Q	(0.02)A	0.00A	-
3Q	(0.02)A	(0.07)E	-
4Q	(0.02)A	(0.08)E	-
YEAR	(0.10)A	(0.19)E	(0.38)E
P/E	NM	NM	NM

Revenue ($ millions)

Yr Dec	—2019—	—2020E—	—2021E—
		Curr	Curr
1Q	0.0A	0.0A	0.0E
2Q	0.0A	0.0A	0.0E
3Q	0.0A	0.0E	0.0E
4Q	0.0A	0.0E	0.0E
YEAR	0.0A	0.0E	0.0E



ORY: Iadademstat Shows Promise in Relapsed SCLC, But Most Likely as Monotherapy

Results from a small trial (CLEPSIDRA; n=14; 10 evaluable for efficacy) of triple combination therapy (iadademstat/carboplatin/etoposide) in second-line small cell lung cancer (SCLC) was reported at ESMO. ORR was 40% (4/10; all PRs). The six-cycle triple therapy caused severe hematological toxicity, but additional cycles of single agent iadademstat did not, which inclined the investigators to conclude that these patients cannot tolerate triple therapy and that iadademstat alone should be further investigated in this disease setting.

- In the 14 biomarker-selected relapsed SCLC patients treated with triple therapy, the 10 evaluable for efficacy achieved four PR and two SD, for an ORR of 40% and a clinical benefit rate of 60%. The ORR compares favorably with response rates for other drugs approved for second-line SCLC such as topotecan (15-24%) and lurbinectedin (35%), or in third-line such as pembrolizumab (19%). The observed clinical benefit also underscores the potential value of biomarkers in patient selection. Mean duration for the four PRs was 4.5 months the two SD lasted more than four months. One PR lasted 21 cycles (15 months; six cycles of combination therapy, 15 cycles of iadademstat monotherapy) and achieved tumor reduction of 90% at cycle 16. Regarding safety, the most common and only concerning triple regimen toxicity was severe hematological alteration in 11 of 14 patients (thrombocytopenia and neutropenia). This toxicity could not be eliminated despite the multiple dosing regimens investigated in the trial, thus the triple regimen was deemed unsuitable for second-line SCLC patients. Despite more than 60 weeks of patient monitoring, iadademstat monotherapy did not produce any hematological, neuronal, renal or hepatic toxicity, but the drug still had therapeutic benefit and therefore it has potential in combination with non-hemotoxic drugs.
- The Phase 2a CLEPSIDRA trial is being conducted at multiple centers in Spain and is a single-arm, open-label trial evaluating time to response, duration of response, ORR and OS of the triple combination of iadademstat plus standard therapy with platinum/etoposide in relapsed SCLC patients having extensive disease. Patients receive four to six cycles of combination therapy based on investigator discretion and then can continue with iadademstat monotherapy. Patients were stratified by certain proprietary biomarkers used to identify LSD1 inhibition-sensitive SCLC tumors. Since the COVID-19 pandemic is delaying monitoring and data cleaning activities, the current results are still preliminary and will mature once the database is locked, even though the formal title of the ESMO presentation is "Final Safety and Efficacy Data from CLEPSIDRA Trial in 2L ED-SCLC".

VALUATION

Our 12-month price target of €15, is based on a DCF analysis using a 35% discount rate that is applied to all cash flows and the terminal value, which is based on a 5x multiple of our projected 2030 operating income of $1.1 billion. We arrive at this valuation by only projecting future revenue from vafidemstat in AD and iadademstat in AML. We view our valuation to be conservative given that it excludes revenue from vafidemstat in ASD, BPD, and ADHD, and from iadademstat in SCLC. Commercial success outside of the two financially modeled indications would serve as upside to our valuation. We believe that ORY.SM has prudently selected areas of unmet need and therefore market demand.

Factors that could impede shares of ORY.SM from achieving our price target include vafidemstat and iadademstat failing to generate statistically significant Phase 3 results in AD and AML, respectively. Also, regulatory agencies could fail to approve these drugs even if both Phase 3 programs are statistical successes, due to the agency viewing the results as not clinically meaningful. Loss of key management personnel could also impede achieving our price target, as could smaller than projected commercial opportunity due to changes in market size, competitive landscape, and drug pricing and reimbursement.

RISKS

- Clinical risk. ORY.SM's clinical staged products could fail to deliver statistically significant results in late-stage clinical trials, substantially reducing the value of ORY.SM's product candidates and therefore our target price.
- Regulatory risk. Even if successful in the clinic, ORY.SM's products could fail to be approved by domestic and/or foreign regulatory bodies, which would reduce ORY.SM’s value and therefore our target price.
- Financing risk. ORY.SM will need additional capital to fund its operations, and such financing may not occur or it could be substantially dilutive to existing investors.
- Competitive risk. For any future approved ORY.SM products, they may not be well adopted in a competitive marketplace, which would adversely affect ORY.SM's value and therefore our target price.
- High stock price volatility. This issue is common among small-cap biotechnology companies with relatively low trading volumes.

COMPANY DESCRIPTION

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as a European champion in epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered clinical stage vafidemstat and iadademstat. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States

Oryzon Genomics SA
Income Statement
Fiscal Year ends December
(in 000, except per share items)

Jonathan Aschoff, Ph.D. (646) 616-2795
jaschoff@roth.com

	2017A	2018A	1Q19	2Q19	3Q19	4Q19	2019A	1Q20A	2Q20A	3Q20E	4Q20E	2020E	2021E
Global iadademstat revenue													
Global vafidemstat revenue													
Collaboration revenue	20												
Total revenue	**20**												
Cost of revenue													
R&D	6,363	8,489	2,610	3,022	3,462	3,553	12,647	4,316	2,731	3,004	3,305	13,356	18,030
G&A	4,502	2,993	876	1,042	742	516	3,176	846	906	915	924	3,590	3,769
Total operating expenses	**10,865**	**11,482**	**3,486**	**4,064**	**4,204**	**4,069**	**15,823**	**5,162**	**3,637**	**3,919**	**4,228**	**16,945**	**21,799**
Operating income	**(10,845)**	**(11,482)**	**(3,486)**	**(4,064)**	**(4,204)**	**(4,069)**	**(15,823)**	**(5,162)**	**(3,637)**	**(3,919)**	**(4,228)**	**(16,945)**	**(21,799)**
Other income (net)	5,659	8,143	2,497	2,516	3,208	3,301	11,522	4,013	2,312			6,325	
Net income (pretax)	**(5,186)**	**(3,339)**	**(989)**	**(1,548)**	**(996)**	**(768)**	**(4,301)**	**(1,149)**	**(1,324)**	**(3,919)**	**(4,228)**	**(10,620)**	**(21,799)**
Net financial & tax	1,047	(1,991)	368	(924)	73	296	(187)	116	(1,102)			(986)	
Net income	**(6,233)**	**(1,348)**	**(1,357)**	**(624)**	**(1,069)**	**(1,064)**	**(4,114)**	**(1,265)**	**(222)**	**(3,919)**	**(4,228)**	**(9,634)**	**(21,799)**
EPS basic	**(0.20)**	**(0.04)**	**(0.04)**	**(0.02)**	**(0.02)**	**(0.02)**	**(0.10)**	**(0.03)**	**(0.00)**	**(0.07)**	**(0.08)**	**(0.19)**	**(0.38)**
EPS diluted	**(0.20)**	**(0.04)**	**(0.04)**	**(0.02)**	**(0.02)**	**(0.02)**	**(0.10)**	**(0.03)**	**(0.00)**	**(0.07)**	**(0.08)**	**(0.19)**	**(0.38)**
Basic shares outstanding	31,711	34,638	38,455	38,638	43,677	45,489	41,589	45,489	45,808	53,539	54,075	49,728	56,778
Diluted shares outstanding	31,711	34,638	38,455	38,638	43,677	45,489	41,565	45,489	45,808	53,539	54,075	49,728	56,778

Source: SEC filings, company press releases, and ROTH Capital Partners

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Disclosures:



Each box on the Rating and Price Target History chart above represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first note written during the past three years. **Distribution Ratings/IB Services** shows the number of companies in each rating category from which Roth or an affiliate received compensation for investment banking services in the past 12 month.

Distribution of IB Services Firmwide

			IB Serv./Past 12 Mos. as of 09/17/20	
Rating	**Count**	**Percent**	**Count**	**Percent**
Buy [B]	**259**	**71.15**	**148**	**57.14**
Neutral [N]	**58**	**15.93**	**19**	**32.76**
Sell [S]	**3**	**0.82**	**2**	**66.67**
Under Review [UR]	**43**	**11.81**	**24**	**55.81**

Our rating system attempts to incorporate industry, company and/or overall market risk and volatility. Consequently, at any given point in time, our investment rating on a stock and its implied price movement may not correspond to the stated 12-month price target.

Ratings System Definitions - ROTH employs a rating system based on the following:

Buy: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return of at least 10% over the next 12 months.

Neutral: A rating, which at the time it is instituted and or reiterated, that indicates an expectation of a total return between negative 10% and 10% over the next 12 months.

Sell: A rating, which at the time it is instituted and or reiterated, that indicates an expectation that the price will depreciate by more than 10% over the next 12 months.

Under Review [UR]: A rating, which at the time it is instituted and or reiterated, indicates the temporary removal of the prior rating, price target and estimates for the security. Prior rating, price target and estimates should no longer be relied upon for UR-rated securities.

Not Covered [NC]: ROTH does not publish research or have an opinion about this security.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used